Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10219327 | 1.00 | NPC1 (0.49) | NPC1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10219317 | 0.94 | NPC1 (0.47) | NPC1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10219319 | 0.94 | NPC1 (0.47) | NPC1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10219298 | 0.89 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL10219302 | 0.89 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL10219310 | 0.89 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL10219343 | 0.85 | PPARD (0.47) | CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10219345 | 0.84 | CYP2D6 (0.47) | NPC1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10219347 | 0.84 | CYP2D6 (0.47) | NPC1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10221626 | 0.82 | SCN4A (0.59) | NPC1CYP2D6SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286974-A1 | Derivative having ppar agonistic activity | PPARD, PPARA, PPARG | NPC1 1742/4885CYP2D6 135/4885SLC6A2 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.